Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift

S Sivasubramaniyam1,2, S A Amiel1,3, P Choudhary1,3

  • 1King's College London, London, UK.

Insights

People with Type 1 diabetes achieving HbA1c below 58 mmol/mol had about 60% of capillary blood glucose readings in range. This suggests a new target for diabetes management may reduce patient anxiety.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Diabetes Management

Background:

  • Current guidelines for Type 1 diabetes (T1D) recommend pre- and post-meal capillary blood glucose (CBG) targets.
  • Achieving optimal glycemic control is crucial for managing T1D.

Purpose of the Study:

  • To evaluate the proportion of daily CBG readings within the 4-10 mmol/l range in individuals with T1D achieving different HbA1c levels.
  • To explore potential new glycemic targets for T1D management.

Main Methods:

  • Analysis of CBG data from 201 adults using continuous subcutaneous insulin infusion (CSII).
  • Participants were categorized into three HbA1c groups: <58 mmol/mol, 58-74 mmol/mol, and ≥75 mmol/mol.
  • Exclusion criteria included short CSII duration, insufficient CBG frequency, pregnancy, haemoglobinopathy, and continuous sensor use.

Main Results:

  • Individuals with HbA1c <58 mmol/mol had approximately 57.3% of CBG readings within the 4-10 mmol/l target range.
  • Higher HbA1c groups showed a lower percentage of readings in range (50.6% and 39.9%).
  • The proportion of readings <4 mmol/l and >10 mmol/l increased with higher HbA1c levels.

Conclusions:

  • Achieving approximately 60% of CBG readings within the 4-10 mmol/l range, with up to 30% exceeding 10 mmol/l, may be a viable target for T1D management.
  • This potential new target could help reduce patient anxiety associated with out-of-range glucose readings.
Abstract

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
669
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.5K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
7.4K